Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

In search of preclinical robustness

Nature Reviews Drug Discovery volume 11, pages 733–734 (2012)Cite this article

Subjects

Abstract

Systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in drug discovery and development.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Begley, G. C. & Ellis, L. M. Raise standards for preclinical cancer research. Nature 483, 531–533 (2012).

    Article  CAS  Google Scholar 

  2. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nature Rev. Drug Discov. 10, 712 (2011).

    Article  CAS  Google Scholar 

  3. Ioannidis, J. P. Why most published research findings are false. PLoS Med. 2, e124 (2005).

    Article  Google Scholar 

  4. Lendrem, D. Statistical support to non-clinical. Pharm. Stat. 1, 71–73 (2002).

    Article  Google Scholar 

  5. Marquardt, D. W. The importance of statisticians. J. Am. Stat. Assoc. 82, 1–7 (1987).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ian S. Peers, Peter R. Ceuppens and Chris Harbron are at AstraZeneca 13F41 Mereside, Alderley Park, Macclesfield SK10 4TG, UK.,

    Ian S. Peers, Peter R. Ceuppens & Chris Harbron

Authors
  1. Ian S. Peers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter R. Ceuppens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Harbron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian S. Peers.

Ethics declarations

Competing interests

Ian S. Peers, Peter R. Ceuppens and Chris Harbron all hold shares in AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peers, I., Ceuppens, P. & Harbron, C. In search of preclinical robustness. Nat Rev Drug Discov 11, 733–734 (2012). https://doi.org/10.1038/nrd3849

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3849

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research